Get in touch

patientliaison@mds-foundation.org
hcp@mds-foundation.org

Phone within the US

1-(800)-637-0839

Outside the US only

1-(609)-298-1035

Address

The MDS Foundation
4573 South Broad St., Suite 150
Yardville, NJ 08620

Patient & Visitor

Healthcare Professional

March 5, 2020

2^nd Regional Symposium on MDS

Speakers

Emanuele Angelucci

Merav Barzilai

May Basood

Rafael Bejar, MD, PhD

Nicolas Bonadies, MD

Rena Buckstein, MD, FRCPC

Pierre Fenaux, MD, PhD

Kalman Filanovski

Mika Geva

Peter L. Greenberg, MD

Marjana M. Kardum Paro

Rotem Keidar

Alan List, MD

Drorit Merkel, MD

Moshe Mittelman, MD

Stephen D. Nimer, MD

Howard S. Oster

Slobodanka Ostojić Kolonić

Inga Mandac Rogulj, MD

Mikkael Sekeres, MD, MS

Galia Stemer

Argiris Symeonidis, MD

Theo de Witte, MD, PhD

Maya Zlotnick

Outputs

Access to the meeting outputs are available below by clicking on each topic.

Our Supporters

Thank you to AbbVie, Celgene Corporation, Neopharm Israel, Novartis, Bristol-Myers Squibb, FibroGen, Inc., Acceleron, Gamida Cell, Janssen Pharmaceuticals Inc., Takeda Oncology, Astex Pharmaceuticals, and Onconova therapeutics for supporting this initiative.

Get in touch

2^nd Regional Symposium on MDS

Speakers

Outputs

Genetics of MDS

Innate Immunity in MDS Pathogenesis

Patient Case

Lessons from the EUMDS Registry

MicroRNA Signature in Myelodysplastic Syndrome

Noninvasive Diagnosis of Myelodysplastic Syndromes (MDS)

Patient Discussion Forum

Iron Chelation and Targeted Therapy in MDS, Shifting the Treatment Paradigm

The Impact of Comorbidities and Infections in the Course and Prognosis of MDS

Optimizing Transfusion Support in MDS. Is What We Are Doing What Patients Want?

Molecular and Clinical Classifications of MDS

The Iron man: when tissue is the issue

High-Risk MDS Patient

Allogeneic Hematopoietic Stem Cell Transplant

Patient Discussion Forum

Systemic inflammatory manifestations in a young adult

Patient Case

Hypomethylating agents in MDS

Beyond HMA (I) – Combinations Therapies in MDS

Precision Medicine in 2020

Patient Case

Paient Discussion Forum

Approach to the Patient with MDS Refractory to Hypomethylating Agents(HMA)

Our Supporters

Get in touch

2nd Regional Symposium on MDS

Speakers

Outputs

Genetics of MDSRafael Bejar, MD, PhD

Genetics of MDS

Innate Immunity in MDS PathogenesisAlan List, MD

Innate Immunity in MDS Pathogenesis

Patient CaseDrorit Merkel, MD

Patient Case

Lessons from the EUMDS RegistryTheo de Witte, MD, PhD

Lessons from the EUMDS Registry

MicroRNA Signature in Myelodysplastic SyndromeInga Mandac Rogulj, MDMarjana M. Kardum ParoSlobodanka Ostojić Kolonić

MicroRNA Signature in Myelodysplastic Syndrome

Noninvasive Diagnosis of Myelodysplastic Syndromes (MDS)Howard S. Oster

Noninvasive Diagnosis of Myelodysplastic Syndromes (MDS)

Patient Discussion ForumMerav Barzilai

Patient Discussion Forum

Iron Chelation and Targeted Therapy in MDS, Shifting the Treatment ParadigmEmanuele Angelucci

Iron Chelation and Targeted Therapy in MDS, Shifting the Treatment Paradigm

The Impact of Comorbidities and Infections in the Course and Prognosis of MDSArgiris Symeonidis, MD

The Impact of Comorbidities and Infections in the Course and Prognosis of MDS

Optimizing Transfusion Support in MDS. Is What We Are Doing What Patients Want?Rena Buckstein, MD, FRCPC

Optimizing Transfusion Support in MDS. Is What We Are Doing What Patients Want?

Molecular and Clinical Classifications of MDSPeter L. Greenberg, MD

Molecular and Clinical Classifications of MDS

The Iron man: when tissue is the issueMaya Zlotnick

The Iron man: when tissue is the issue

High-Risk MDS PatientMika Geva

High-Risk MDS Patient

Allogeneic Hematopoietic Stem Cell TransplantTheo de Witte, MD, PhD

Allogeneic Hematopoietic Stem Cell Transplant

Patient Discussion ForumMay Basood

Patient Discussion Forum

Systemic inflammatory manifestations in a young adultNicolas Bonadies, MD

Systemic inflammatory manifestations in a young adult

Patient CaseGalia Stemer

Patient Case

Hypomethylating agents in MDSPierre Fenaux, MD, PhD

Hypomethylating agents in MDS

Beyond HMA (I) – Combinations Therapies in MDSMikkael Sekeres, MD, MS

Beyond HMA (I) – Combinations Therapies in MDS

Precision Medicine in 2020Stephen D. Nimer, MD

Precision Medicine in 2020

Patient CaseRotem Keidar

Patient Case

Paient Discussion ForumMoshe Mittelman, MD

Paient Discussion Forum

Approach to the Patient with MDS Refractory to Hypomethylating Agents(HMA)Kalman Filanovski

Approach to the Patient with MDS Refractory to Hypomethylating Agents(HMA)

Our Supporters

2^nd Regional Symposium on MDS